Benzinga | Oct 27, 2021 12:08PM EDT

Vertex Reports Its Supplement To New Drug Application For TRIKAFTA In Patients Ages 6-11 Accepted By Health Canada For Priority Review

Vertex Pharmaceuticals Incorporated (Canada) (NASDAQ:VRTX) today announced that its Supplement to a New Drug Submission for PrTRIKAFTA(r) (elexacaftor/tezacaftor/ivacaftor and ivacaftor) has been accepted for Priority Review by Health Canada for the treatment of cystic fibrosis (CF) in people ages 6-11 years.

Vertex will also submit this indication in parallel to both the Canadian Agency for Drugs and Technologies in Health (CADTH) and the Institut national d'excellence en sant? et en services sociaux (INESSS) in Quebec for Health Technology Assessments.

"We are pleased that TRIKAFTA 6-11 has been accepted for Priority Review by Health Canada and we look forward to bringing this product to patients as soon as possible," said Duncan McKechnie, Senior Vice President, North America Commercial Operations, Vertex Pharmaceuticals.